INTRODUCTION: Normal immature hematopoietic progenitors are relatively well preserved in most patients newly diagnosed with chronic myeloid leukemia, but tend to decline rapidly with time. Such exhaustion could reflect a suppressive effect of the Philadelphia positive clone expansion and/or be induced by Interferon-alpha treatment. MATERIALS AND METHODS: A total of 51 CML patients were classified into three groups. Newly diagnosed untreated patients were group A (n=30). Of the 21 treated individuals with Interferon-alpha, for at least 12 months, 15 showed no cytogenetic response (group B) while six showed persisting major/complete response (group C). Patients belonging to groups A and B were mobilized with chemotherapy plus G-CSF while pati...
Treatment with interferon-alpha is effective for chronic myelogenous leukemia in the chronic phase (...
Interferon-alpha may be better than cytotoxic drugs in the long-term management of patients with chr...
Although interferon-alpha (IFN-alpha) induces hematologic remissions in 70% to 80% of patients with ...
INTRODUCTION: Normal immature hematopoietic progenitors are relatively well preserved in most patien...
Ph chromosome occurs in nearly all patients with CML, and eliminating Ph-positive clone is a major t...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
BACKGROUND: Standard or conventional treatment of chronic myeloid leukemia (CML) had little effect o...
PURPOSE: To determine, in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous le...
Chronic myelogenous leukemia (CML) progenitors show decreased adhesion to stroma and fibronectin (FN...
International audienceInterferon alpha (IFN-alpha) is used to treat chronic myelogenous leukaemia (C...
We investigated the effects of brief (2 h) and continuous exposure to recombinant interferon-alpha2a...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
We treated 114 Ph'+ chronic myeloid leukemia (CML) patients, 105 of whom were in chronic phase (CP) ...
Fourteen patients with chronic myelogenous leukemia in chronic phase who had achieved hematological ...
Treatment with interferon-alpha is effective for chronic myelogenous leukemia in the chronic phase (...
Interferon-alpha may be better than cytotoxic drugs in the long-term management of patients with chr...
Although interferon-alpha (IFN-alpha) induces hematologic remissions in 70% to 80% of patients with ...
INTRODUCTION: Normal immature hematopoietic progenitors are relatively well preserved in most patien...
Ph chromosome occurs in nearly all patients with CML, and eliminating Ph-positive clone is a major t...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
BACKGROUND: Standard or conventional treatment of chronic myeloid leukemia (CML) had little effect o...
PURPOSE: To determine, in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous le...
Chronic myelogenous leukemia (CML) progenitors show decreased adhesion to stroma and fibronectin (FN...
International audienceInterferon alpha (IFN-alpha) is used to treat chronic myelogenous leukaemia (C...
We investigated the effects of brief (2 h) and continuous exposure to recombinant interferon-alpha2a...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
We treated 114 Ph'+ chronic myeloid leukemia (CML) patients, 105 of whom were in chronic phase (CP) ...
Fourteen patients with chronic myelogenous leukemia in chronic phase who had achieved hematological ...
Treatment with interferon-alpha is effective for chronic myelogenous leukemia in the chronic phase (...
Interferon-alpha may be better than cytotoxic drugs in the long-term management of patients with chr...
Although interferon-alpha (IFN-alpha) induces hematologic remissions in 70% to 80% of patients with ...